ORIC Oric Pharmaceuticals, Inc. | US68622P1093
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 0 | 0 | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -1,61 | -1,47 | 10.01% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 11 | 13 | 15.38% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |